참고문헌 (55)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82(11):844-51. 

   상세보기

2. Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open-angle glaucoma blindness. Acta Ophthalmol 2014;92(5):421-25. 

   상세보기

3. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11):2081-90. 

   상세보기

4. Sharif NA. Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision. Neural Regen Res 2018;13(7):1145-50. 

   상세보기

5. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA 2014;311(18):1901-11. 

   상세보기

6. Terminology and guidelines for glaucoma (4th edition) 2014. European Glaucoma Society Guidelines. Available from http://www.icoph.org/dynamic/attachments/resources/egs_guidelines_4_english.pdf. Accessed August 16, 2021. 

7. Nguyen QH. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence 2014;8:853-64. 

   상세보기

8. Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 2010;4:1-9. 

   상세보기

9. Ong SS, Sanka K, Mettu PS, et al. Resident compliance with the american academy of ophthalmology preferred practice pattern guidelines for primary open-angle glaucoma. Ophthalmology 2013;120(12):2462-9. 

   상세보기

10. Nguyen QH. The role of prostaglandin analogues in the treatment of glaucoma in the 21st century. Int Ophthalmol Clin 2004;44(2):15-27. 

    상세보기

11. Iester M. Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clin Ophthalmol 2008;2(3):517-23. 

    상세보기

12. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000;44(Suppl 2):S119-29. 

    상세보기

13. Greig SL, Deeks ED. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension. Drugs Aging 2015;32(3):251-60. 

    상세보기

14. Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging 2008;25(9):729-59. 

    상세보기

15. Cheng JW, Li Y, Wei RL. Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost. Ophthalmic Res 2009;42(2):99-105. 

    상세보기

16. Dzhumataeva ZA. [Prostaglandin analogues in glaucoma treatment]. Vestn Oftalmol 2016;132(4):62-7. 

    

17. Lusthaus JA, Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. Expert Opin Drug Saf 2017;16(9):1071-8. 

    상세보기

18. Prum BE, Jr., Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern(®) Guidelines. Ophthalmology 2016;123(1):P41-111. 

19. Glaucoma: diagnosis and management. National Institute for Health and Care Excellence. Available from https://www.nice.org.uk/guidance/ng81/chapter/Recommendations#treatment. Accessed August 16, 2021. 

20. Liu Y, Zhao J, Zhong X, Wei Q, Huang Y. Efficacy and safety of brinzolamide as add-on to prostaglandin analogues or β-Blocker for glaucoma and ocular hypertension: A systematic review and meta-analysis. Front Pharmacol 2019;10:679. 

    상세보기

21. Joshi SR, Akat PB, Ramanand JB, Ramanand SJ, Karande VB, Jain SS. Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma. Indian J Ophthalmol 2013;61(12):765-7. 

    상세보기

22. Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21(4):337-48. 

    상세보기

23. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124(9):1230-8. 

    상세보기

24. Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 2011;39(2):91-2. 

    상세보기

25. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. 

    상세보기

26. Aihara M, Adachi M, Matsuo H, Togano T, Fukuchi T, Sasaki N. Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Acta Ophthalmol 2017;95(8):e720-6. 

    상세보기

27. Fechtner RD, Myers JS, Hubatsch DA, Budenz DL, DuBiner HB. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial. Eye (Lond) 2016;30(10):1343-50. 

    상세보기

28. Michaud JE, Friren B. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132(2):235-43. 

    상세보기

29. Yoshikawa K, Kozaki J, Maeda H. Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2014;8:389-99. 

    상세보기

30. Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in openangle glaucoma or ocular hypertension. Ophthalmology 2014;121(12):2348-55. 

    상세보기

31. Feldman RM, Tanna AP, Gross RL, et al. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology 2007;114(7):1248-54. 

    상세보기

32. Feldman RM, Katz G, McMenemy M, Hubatsch DA, Realini T. A randomized trial of fixed-dose combination brinzolamide 1%/brimonidine 0.2% as adjunctive therapy to travoprost 0.004. Am J Ophthalmol 2016;165:188-97. 

    상세보기

33. Hollo G, Chiselita D, Petkova N, et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006;16(6):816-23. 

    상세보기

34. Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology 2008;115(10):1728-34. 

    상세보기

35. Nguyen QH, McMenemy MG, Realini T, Whitson JT, Goode SM. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. J Ocul Pharmacol Ther 2013;29(3):290-7. 

    상세보기

36. Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol 2000;44(Suppl 2):S163-8. 

    상세보기

37. Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin 2008;24(5):1435-42. 

    상세보기

38. Katz G, Dubiner H, Samples J, Vold S, Sall K. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%. JAMA Ophthalmol 2013;131(6):724-30. 

    상세보기

39. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N Engl J Med 2009;360(11):1113-24. 

    상세보기

40. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120(6):701-13. 

    상세보기

41. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991;109(8):1090-5. 

42. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120(10):1268-79. 

    상세보기

43. Costagliola C, Del Prete A, Verolino M, et al. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol 2002;240(5):379-86. 

    상세보기

44. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112(7):1177-85. 

    상세보기

45. Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 2005;21(4):503-8. 

    상세보기

46. Miura K, Ito K, Okawa C, Sugimoto K, Matsunaga K, Uji Y. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. J Glaucoma 2008;17(3):233-7. 

    상세보기

47. Puscas I, Coltau M. Prostaglandins with vasodilating effects inhibit carbonic anhydrase while vasoconstrictive prostaglandins and leukotriens B4 and C4 increase CA activity. Int J Clin Pharmacol Ther 1995;33(3):176-81. 

    상세보기

48. U.S Food and Drug Administration. Drug@FDA: FDA-Approved Drugs-SIMBRINZA (NOVARTIS). Available from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?eventoverview.process&ApplNo204251. Accessed July 17, 2021. 

49. Ministry of Food and Drug Safety. SIMBRINZA ophthalmic suspension (NOVARTIS KOREA Co. Ltd). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq201503767. Accessed July 17, 2021. 

50. Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Curr Opin Ophthalmol 1997;8(2):55-8. 

    상세보기

51. Whitson JT, Realini T, Nguyen QH, McMenemy MG, Goode SM. Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension. Clin Ophthalmol 2013;7:1053-60. 

    상세보기

52. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998;126(3):400-8. 

53. Topouzis F, Goldberg I, Bell K, et al. Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension. Eur J Ophthalmol 2021;31(1):103-11. 

    상세보기

54. Ministry of Food and Drug Safety. AZOPT ophthalmic suspension (brinzolamide) (NOVARTIS KOREA. Co. Ltd.) Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq200109116. Accessed August 17, 2021. 

55. U.S Food and Drug Administration. Drug@FDA: FDA-Approved Drugs-AZOPT. NOVARTIS. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020816s023lbl.pdf. Accessed August 17, 2021.